Figure 2.
Longitudinal monitoring of specific and apparent nonspecific FVIII-binding antibodies and FVIII inhibitors in HIPS-ITI patient 2 during HIPS and HIPS-ITI. (A) FVIII-binding (specific) antibody titers (IgG1, IgG2, IgG3, IgG4, IgA, IgM; open circles, open squares, open triangles as indicated), FVIII-binding (apparent nonspecific) antibody titers (IgG1, IgG2, IgG3, IgG4, IgA; filled circles, filled squares as indicated), and FVIII inhibitors (BU/mL) for HIPS-ITI patient 2. The red dotted line represents the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). The yellow star marks the initiation of ITI treatment at ED16. The continuous vertical line indicates the end of HIPS and the start of HIPS-ITI. (B) Mean KA for FVIII-binding (specific) antibodies differentiated for individual IgG subclasses and FVIII inhibitors (BU/mL) for HIPS-ITI patient 2. Data for apparent KAs include the 95% CIs for up to 2 affinity clusters for each IgG subclass (dark colors: cluster 1; light colors: cluster 2). The red dotted line represents the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). The yellow star marks the initiation of ITI treatment at ED16. The continuous vertical line indicates the end of HIPS and the start of HIPS-ITI.

Longitudinal monitoring of specific and apparent nonspecific FVIII-binding antibodies and FVIII inhibitors in HIPS-ITI patient 2 during HIPS and HIPS-ITI. (A) FVIII-binding (specific) antibody titers (IgG1, IgG2, IgG3, IgG4, IgA, IgM; open circles, open squares, open triangles as indicated), FVIII-binding (apparent nonspecific) antibody titers (IgG1, IgG2, IgG3, IgG4, IgA; filled circles, filled squares as indicated), and FVIII inhibitors (BU/mL) for HIPS-ITI patient 2. The red dotted line represents the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). The yellow star marks the initiation of ITI treatment at ED16. The continuous vertical line indicates the end of HIPS and the start of HIPS-ITI. (B) Mean KA for FVIII-binding (specific) antibodies differentiated for individual IgG subclasses and FVIII inhibitors (BU/mL) for HIPS-ITI patient 2. Data for apparent KAs include the 95% CIs for up to 2 affinity clusters for each IgG subclass (dark colors: cluster 1; light colors: cluster 2). The red dotted line represents the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). The yellow star marks the initiation of ITI treatment at ED16. The continuous vertical line indicates the end of HIPS and the start of HIPS-ITI.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal